<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297933</url>
  </required_header>
  <id_info>
    <org_study_id>10-007681</org_study_id>
    <nct_id>NCT01297933</nct_id>
  </id_info>
  <brief_title>Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease</brief_title>
  <acronym>Omegaven</acronym>
  <official_title>Intravenous Omega-3 Fatty Acid (Omegaven) for Pediatric Patients With Total Parenteral Nutrition Associated Liver Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <brief_summary>
    <textblock>
      A compassionate use protocol to provide Omegaven to pediatric patients with parenteral
      nutrition (PN) dependence and parenteral nutrition associated liver disease (PNALD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Omegaven is an intravenous fat emulsion (IFE) comprised of omega-3 fatty acids derived from
      fish oil. It will be used in an open label compassionate use treatment protocol, as an
      alternative to soybean oil (omega-6), as the sole IFE source of parenteral nutrition in an
      effort to reduce and/or reverse parenteral nutrition associated liver disease. The study will
      evaluate the safety and efficacy of Omegaven use in pediatric patients with PN dependence and
      PNALD.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Cholestasis</condition>
  <condition>Short Bowel Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven</intervention_name>
    <description>10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PN dependence due to congenital or acquired gastrointestinal disease

          -  Predicted PN requirement for at least an additional 30 days

          -  Parenteral nutrition associated liver disease (PNALD), defined as two conjugated
             bilirubin levels &gt;= 2 mg/dL at least one week apart, must be obtained to demonstrate
             persistence of PNALD

          -  Failure to respond to standard therapies which may include cycling PN, reduction in
             the dose of soybean derived IFE, attempts to advance enteral feeds, ursodiol,
             metronidazole, and avoidance of excessive caloric provision

          -  signed parent or legal guardian informed consent

        Exclusion Criteria:

          -  Acute treatable infection (e.g. urinary tract infection, sepsis)

          -  Known allergy to egg or fish protein

          -  Contraindications to Omegaven

          -  Pregnancy

          -  Serum triglyceride level greater than 400 mg/dL at baseline

          -  History of severe hemolytic disorders or INR greater than 1.5 at baseline (INR cutoff
             of greater than 2 for infants less than 1 week of age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Mascarenhas, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Mascarenhas, MBBS</last_name>
    <phone>215-590-2997</phone>
    <email>mascarenhas@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan A. Becker, RN, BSN, CCRC</last_name>
    <phone>267-426-0269</phone>
    <email>beckers@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Maria Mascarenhas, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alwayn IP, Gura K, Nos√© V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar;57(3):445-52. Epub 2005 Jan 19.</citation>
    <PMID>15659701</PMID>
  </reference>
  <reference>
    <citation>Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):209-15. doi: 10.1097/MPG.0b013e318182c8f6.</citation>
    <PMID>19179884</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Parsons SK, Bechard LJ, Henderson T, Dorsey M, Phipatanakul W, Duggan C, Puder M, Lenders C. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005 Oct;24(5):839-47.</citation>
    <PMID>16029913</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, Lopes S, Duggan C, Puder M. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar;121(3):e678-86. doi: 10.1542/peds.2007-2248.</citation>
    <PMID>18310188</PMID>
  </reference>
  <reference>
    <citation>Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep;250(3):395-402. doi: 10.1097/SLA.0b013e3181b36657.</citation>
    <PMID>19661785</PMID>
  </reference>
  <reference>
    <citation>Van Aerde JE, Duerksen DR, Gramlich L, Meddings JB, Chan G, Thomson AB, Clandinin MT. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res. 1999 Feb;45(2):202-8.</citation>
    <PMID>10022591</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Maria Mascarenhas</investigator_full_name>
    <investigator_title>Section Chief, Clinical Nutrition</investigator_title>
  </responsible_party>
  <keyword>parenteral nutrition associated liver disease</keyword>
  <keyword>cholestasis</keyword>
  <keyword>short bowel syndrome</keyword>
  <keyword>Omegaven</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

